Induction Therapy With Docetaxel, Cisplatin, 5-Fluoro Uracil and Pembrolizumab in Untreated Locally-advanced Unresectable Squamous Cell Head and Neck Carcinoma (Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. PICH Study)

Trial Profile

Induction Therapy With Docetaxel, Cisplatin, 5-Fluoro Uracil and Pembrolizumab in Untreated Locally-advanced Unresectable Squamous Cell Head and Neck Carcinoma (Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. PICH Study)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Pembrolizumab (Primary) ; Carboplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms PICH Study
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.
    • 02 Oct 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
    • 02 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top